Ms Amelia Lau
Research Associate
Centre for Cancer Biology
College of Health
Amelia is a Research Assistant in the Molecular Pathology group of Centre for Cancer Biology. She received her B.Sc. Biotechnology from Monash University and M.Sc. Biotechnology from The Australian National University.
Amelia joined the University in 2023 after working at the Cancer Science Institute of Singapore (National University of Singapore) for 15 years. She is an experienced and passionate molecular biologist specializing in cancer biology. 15 years of diverse hands-on experience in clinical trials and molecular techniques including, but not limited to mammalian cell culture, mouse work, western blot, cell inhibition drug assay, qPCR and lentivirus work. Extensive knowledge with proven success in laboratory maintenance and laboratory safety management. Self- motivated with good organizational and interpersonal skills. Keen to learn and responsible. Authored in numerous scientific journals.
| Year | Citation |
|---|---|
| 2024 | Ong, K. O. K., Mok, M. M. H., Niibori-Nambu, A., Du, L., Yanagida, M., Wang, C. Q., . . . Osato, M. (2024). Activation of NOTCH signaling impedes cell proliferation and survival in acute megakaryoblastic leukemia. Experimental Hematology, 137(104255), 7 pages. Scopus1 WoS1 Europe PMC2 |
| 2020 | Chong, W. Q., Lim, C. M., Sinha, A. K., Tan, C. S., Chan, G. H. J., Huang, Y., . . . Goh, B. C. (2020). Integration of antiangiogenic therapy with cisplatin and gemcitabine chemotherapy in patients with nasopharyngeal carcinoma. Clinical Cancer Research, 26(20), 5320-5328. Scopus19 WoS17 Europe PMC15 |
| 2020 | Kong, L. R., Ong, R. W., TariD, T. Z., Salleh, N. A. B. M., Lau, J. A., & Goh, B. C. (2020). Targeting codon 158 p53-mutant cancers via the induction of p53 acetylation. Nature Communications, 11(1), 1-17. Scopus27 WoS28 Europe PMC23 |
| 2016 | Ong, P. S., Wang, L., Chia, D. M. H., Seah, J. Y. X., Kong, L. R., Thuya, W. L., . . . Goh, B. C. (2016). A novel combinatorial strategy using Seliciclib® and Belinostat® for eradication of non-small cell lung cancer via apoptosis induction and BID activation. Cancer Letters, 381(1), 49-57. Scopus43 WoS41 Europe PMC31 |
| 2015 | Wang, L. Z., Goh, S. H., Wong, A. L. A., Thuya, W. L., Lau, J. Y. A., Wan, S. C., . . . Goh, B. C. (2015). Validation of a rapid and sensitive LC-MS/ MS method for determination of exemestane and its metabolites, 17β-hydroxyexemestane and 17β-hydroxyexemestane-17-O-β-D-glucuronide: Application to human pharmacokinetics study. Plos One, 10(3), 13 pages. Scopus18 WoS162 Europe PMC13 |
| 2015 | Tan, T. Z., Huang, R. Y. -J., Miow, Q. H., Ye, J., Wong, M. K., Lau, J. A., . . . Thiery, J. P. (2015). Quantitate epithelial-mesenchymal transition in ovarian cancer. CLINICAL CANCER RESEARCH, 21(16_Supplement), 2 pages. |
| 2014 | Wang, L. -Z., Soo, R. A., Thuya, W. L., Wang, T. T., Guo, T., Lau, J. A., . . . Goh, B. C. (2014). Exosomal protein FAM3C as a potential novel biomarker for non-small cell lung cancer.. JOURNAL OF CLINICAL ONCOLOGY, 32(15), 1 page. WoS3 |
| 2014 | Wang, L. -Z. (2014). Hsp27 Expression Does Not Affect Anti-Cancer Drug Sensitivity but Promote Cell Proliferation of Lung Squamous Cell Carcinoma In Vitro. JPDM, 1(1). |
| 2014 | Wang, L. Z., Ramírez, J., Yeo, W., Chan, M. Y. M., Thuya, W. L., Lau, J. Y. A., . . . Goh, B. C. (2014). Correction: Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients (PLoS ONE). Plos One, 9(1). Scopus1 |
| 2014 | Miow, Q. H., Tan, T. Z., Ye, J., Lau, J. A., Yokomizo, T., Thiery, J. P., & Mori, S. (2014). Epithelial-mesenchymal status renders differential responses to cisplatin in ovarian cancer. Oncogene, 34(15), 1899-1907. Scopus99 WoS96 Europe PMC84 |
| 2014 | Rempel, R. E., Jiang, X., Fullerton, P., Tan, T. Z., Ye, J., Lau, J. A., . . . Friedman, D. R. (2014). Utilization of the Eμ-Myc mouse to model heterogeneity of therapeutic response. Molecular Cancer Therapeutics, 13(12), 3219-3229. Scopus18 WoS15 Europe PMC17 |
| 2013 | Tan, T. Z., Miow, Q. H., Huang, R. Y. J., Wong, M. K., Ye, J., Lau, J. A., . . . Mori, S. (2013). Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer. EMBO Molecular Medicine, 5(7), 1051-1066. Scopus184 WoS177 Europe PMC176 |
| 2013 | Wang, L. Z., Ramírez, J., Yeo, W., Chan, M. Y. M., Thuya, W. L., Lau, J. Y. A., . . . Goh, B. C. (2013). Glucuronidation by UGT1A1 Is the Dominant Pathway of the Metabolic Disposition of Belinostat in Liver Cancer Patients. Plos One, 8(1), 10 pages. Scopus62 WoS110 Europe PMC49 |
| 2013 | Wang, L. Z., Thuya, W. L., Toh, D. S. L., Lie, M. G. L., Lau, J. Y. A., Kong, L. R., . . . Goh, B. C. (2013). Quantification of L-ergothioneine in human plasma and erythrocytes by liquid chromatography-tandem mass spectrometry. Journal of Mass Spectrometry, 48(3), 406-412. Scopus24 WoS22 Europe PMC18 |
| 2012 | Miow, Q. H., Tan, T. Z., Ye, J., Lau, J. A., Thiery, J. P., & Mori, S. (2012). Identification of Functional Targets of Serous Ovarian Cancer. EUROPEAN JOURNAL OF CANCER, 48, S138. |
| 2011 | Kong, L. R., Wang, L., Wan, S. C., Lau, J. A., Nye, P. L., Lwin, T. W., & Goh, B. C. (2011). The identification of cisplatin resistance pathways in lung squamous cell carcinoma and approaches to overcome resistance. CANCER RESEARCH, 71(18_Supplement), 4 pages. |
Connect With Me
External Profiles
